There have been no reports of adverse events related to the recall, which is being conducted out of an 'abundance of caution'

Variables in the model include age at onset, duration, nail involvement, erythematous lunula, onychorrhexis, oil drop, subungual hyperkeratosis

Moderate to good interrater reliabilities exhibited by most body sites; good to excellent intrarater reliabilities also seen

Facial Vitiligo Area Scoring Index, using the fingertip unit, has high accuracy and intrarater reliability

Air pollution may trigger psoriasis flares in individuals with chronic plaque psoriasis

Grade A recommendation reaffirms 2016 recommendation for asymptomatic, nonpregnant adults and teens at increased risk

Strongest predictors of sleep impairment include anxiety and depression levels, pruritus exacerbation at night, in morning

Differences in socioeconomic status contribute to survival disparities for Hispanic Black and White patients

However, first-line antibiotic coverage against MRSA more often given to persons experiencing homelessness

Scale uses extent of scalp hair loss as primary basis for severity rating and includes four secondary features

Meta-analysis of genome-wide association studies adds to knowledge of genetic contribution to acne susceptibility

Those at high risk of skin cancer accurately assessed risk and reported lower likelihood of future tanning bed use

Overall survival longer in patients receiving first-line treatment with nivolumab plus chemo or nivolumab plus ipilimumab versus chemo alone

Greatest increase in first end point of total hair count at 24 weeks was seen for 0.5 mg/day dutasteride

Mohs micrographic surgery is less expensive and results in 2.22 weeks of perfect health gained over five years versus WLE

Risk factors for metastases include age, male sex, and immunosuppression

If approved, the two-shot regimen would become the first approved for use in children this young

New algorithm uses multistage fusion process that includes clinical images, dermoscopy images, and patient meta-data

However, proportion of reporting articles including at least 20 percent non-White representation unchanged at 38.1 percent

Significantly more patients achieved ≥90 percent improvement in PASI at week 24 with risankizumab versus FAE

Approval based on two Phase 3 trials showing more than 50 percent of patients receiving Skyrizi achieved ACR20 response at 24 weeks

Findings show modest, but significant, benefit from either compassion-based or mindfulness-based self-help

Standardized incidence ratio was 3.0 during first year of follow-up after VTE and decreased to 1.5 during subsequent years